Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Mustang Bio Inc MBIO

Healthcare Biotechnology
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB... see more

Current News (NDAQ:MBIO)

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

GlobeNewswire July 7, 2025

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

GlobeNewswire March 5, 2025

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

GlobeNewswire February 27, 2025

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire February 11, 2025

Mustang Bio Announces Closing of $8 Million Public Offering

GlobeNewswire February 10, 2025

Mustang Bio Announces Pricing of $8 Million Public Offering

GlobeNewswire February 6, 2025

Mustang Bio Announces Reverse Stock Split

GlobeNewswire January 14, 2025

Mustang Bio Receives Positive Listing Determination from Nasdaq

GlobeNewswire November 12, 2024

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

GlobeNewswire November 7, 2024
View More News ››

Opinion & Analysis (NDAQ:MBIO)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:MBIO)

Buy buddy buy.

Otherwise it is FOMO for you guys out there today anyway
coolfooldumbguy - July 9, 2025

Buy buddy buy because it's taking off this morning.

Otherwise you guys out there will be left behind by this stock today and so FOMO anyway
coolfooldumbguy - July 7, 2025

MBIO.....bouncing off the lows in AH

On watch
Iseneschal - February 27, 2025

MBIO....next announcement will be.........

All the 23 cent warrants have been exercised ; ) And welcome to all the new Bagholders
Iseneschal - June 17, 2024

RE:MBIO.....Trust me...ur all going to get screwed. NR this a.m

I've been wrong before ; ) Up only 600% on 1 billion shares....LM*AO !!!!! No position Definetly not now....JMHO...you be the...
Iseneschal - June 17, 2024

MBIO.....Trust me...ur all going to get screwed. NR this a.m

Go ahead and Chase ..... The MM's are licking their chops right now ....salivating for the opening bell to dump all the shares they...
Iseneschal - June 17, 2024
View more Bullboard ››

FPX Nickel Corp.

FPX Nickel Corp.

FPX Nickel Corp., a junior nickel mining company, engages in the acquisition, exploration, and development of mineral ...
View More »

Podcasts